Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

× No keyword cloud information.

11 in total

Review 1. Eosinophilic myeloproliferative disorders.

Authors: Amy D Klion
Journal: Hematology Am Soc Hematol Educ Program Date: 2011

2. Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia.

Authors: Nicola Sgherza; Antonella Vita Russo Rossi; Paolo Colonna; Paola Carluccio; Mario Delia; Giorgina Specchia
Journal: Int J Hematol Date: 2013-07-24 Impact factor: 2.490

3. Chemotherapy-induced Cardiotoxicity.

Authors: Maria Florescu; Mircea Cinteza; Dragos Vinereanu
Journal: Maedica (Bucur) Date: 2013-03

Review 4. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors: Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal: Clin Biochem Date: 2014-11-07 Impact factor: 3.281

Review 5. Chronic myelogenous leukemia: treatment and monitoring.

Authors: Nikolas von Bubnoff; Justus Duyster
Journal: Dtsch Arztebl Int Date: 2010-02-19 Impact factor: 5.594

Review 6. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Authors: Carlo Gabriele Tocchetti; Christian Cadeddu; Daniela Di Lisi; Saveria Femminò; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Claudia Penna; Alessia Pepe; Paolo Spallarossa; Gilda Varricchi; Concetta Zito; Pasquale Pagliaro; Giuseppe Mercuro
Journal: Antioxid Redox Signal Date: 2017-05-15 Impact factor: 8.401

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Review 1. Eosinophilic myeloproliferative disorders.

2. Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia.

3. Chemotherapy-induced Cardiotoxicity.

Review 4. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Review 5. Chronic myelogenous leukemia: treatment and monitoring.

Review 6. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

7. Cardiotoxicity associated with targeted cancer therapies.

Review 8. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.

Review 9. Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.

Review 10. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.